LLY

1,020.69

-0.81%↓

JNJ

243.4

-0.72%↓

ABBV

224.52

-1.08%↓

NVS

165.19

-0.73%↓

MRK

119.22

-2.61%↓

LLY

1,020.69

-0.81%↓

JNJ

243.4

-0.72%↓

ABBV

224.52

-1.08%↓

NVS

165.19

-0.73%↓

MRK

119.22

-2.61%↓

LLY

1,020.69

-0.81%↓

JNJ

243.4

-0.72%↓

ABBV

224.52

-1.08%↓

NVS

165.19

-0.73%↓

MRK

119.22

-2.61%↓

LLY

1,020.69

-0.81%↓

JNJ

243.4

-0.72%↓

ABBV

224.52

-1.08%↓

NVS

165.19

-0.73%↓

MRK

119.22

-2.61%↓

LLY

1,020.69

-0.81%↓

JNJ

243.4

-0.72%↓

ABBV

224.52

-1.08%↓

NVS

165.19

-0.73%↓

MRK

119.22

-2.61%↓

Home・Aandelen Lijst・Avita Therapeutics Inc

Avita Therapeutics Inc

Gesloten

5.07 1.4

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

4.85

Max

5.12

Belangrijke statistieken
By Trading Economics
Inkomsten	1.6M -12M
Verkoop	554K 18M
EPS	-0.536
Winstmarge	-65.968
Werknemers	226
EBITDA	1.6M -9.7M

Aanbevelingen
By TipRanks
Aanbevelingen	Buy
12 Maanden Prognose	-16.51% downside

Dividenden
By Dow Jones
Volgende Winsten	7 mei 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	25M 149M
Vorige openingsprijs	3.67
Vorige sluitingsprijs	5.07

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

8.83 / 9.77 Steun & Weerstand

Avita Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

25 feb 2026, 23:25 UTC

Populaire aandelen

Stocks to Watch: C3.ai, Salesforce, Pure Storage, Zoom

25 feb 2026, 23:15 UTC

Winsten

Salesforce Sees Stable Growth; CEO Dismisses Talk of AI-Fueled 'SaaS-Pocalypse' -- 2nd Update

25 feb 2026, 23:54 UTC

Marktinformatie

Gold Steady Ahead of U.S.-Iran Talks -- Market Talk

25 feb 2026, 23:47 UTC

Winsten

Ferrovial 4Q Net EUR197M >FER.MC

25 feb 2026, 23:45 UTC

Winsten

Ferrovial 4Q Rev EUR2.72B >FER.MC

25 feb 2026, 23:42 UTC

Winsten

Nvidia Beats Back Bubble Fears With Record $68 Billion Sales in Fourth Quarter -- 4th Update

25 feb 2026, 23:38 UTC

Marktinformatie

Nikkei May Rise, Tracking Wall Street's Gains -- Market Talk

25 feb 2026, 23:25 UTC

Winsten

Trip.com: Company's Business Operations Remain Normal >TCOM

25 feb 2026, 23:25 UTC

Winsten

Trip.com Gives Update on Investigation by China's State Administration for Market Regulation >TCOM

25 feb 2026, 23:25 UTC

Winsten

Trip.com: Cannot Predict Status or Results of Investigation, Will Provide Updates on Conclusion >TCOM

25 feb 2026, 23:25 UTC

Winsten

Trip.com Increase in FY Profit Primarily Due to Gain From Investments >TCOM

25 feb 2026, 23:25 UTC

Winsten

Trip.com Will Continue to Communicate With SAMR on Compliance With Regulatory Requirements >TCOM

25 feb 2026, 23:25 UTC

Winsten

Trip.com: SAMR Investigation Related to China's Anti-monopoly Law >TCOM

25 feb 2026, 23:25 UTC

Winsten

Trip.com: Investigation Ongoing, Company Is Cooperating With SAMR >TCOM

25 feb 2026, 23:25 UTC

Winsten

Trip.com Co-founders Min Fan, Qi Ji Resign From Positions >TCOM

25 feb 2026, 23:25 UTC

Winsten

Trip.com: Fan Resigned as Director and President; Ji Resigned as a Director >TCOM

25 feb 2026, 23:25 UTC

Winsten

Trip.com FY Rev CNY62.4B, Up 17% >TCOM

25 feb 2026, 23:25 UTC

Winsten

Trip.com FY Net CNY33.3B Vs. Net CNY17.1B >TCOM

25 feb 2026, 23:25 UTC

Winsten

Trip.com FY EPS CNY47.67 >TCOM

25 feb 2026, 23:06 UTC

Winsten

Correction to Nvidia Fourth Quarter Results Article -- WSJ

25 feb 2026, 23:01 UTC

Winsten

Nvidia Beats Back Bubble Fears With Record $68 Billion Sales in Fourth Quarter -- 3rd Update

25 feb 2026, 23:00 UTC

Marktinformatie

Winsten

Global Equities Roundup: Market Talk

25 feb 2026, 23:00 UTC

Marktinformatie

Winsten

Nvidia: Chinese Competitors Pose Risk to U.S. Dominance in AI -- Market Talk

25 feb 2026, 22:56 UTC

Marktinformatie

Winsten

Nvidia CEO Says Customers Can't Grow Revenue Without Compute -- Market Talk

25 feb 2026, 22:43 UTC

Winsten

Acquisities, Fusies, Overnames

Paramount Streaming Revenue Rises, but TV Segment Faces Headwinds -- WSJ

25 feb 2026, 22:40 UTC

Marktinformatie

Winsten

Nvidia Says Agentic AI Has Reached Inflection Point -- Market Talk

25 feb 2026, 22:40 UTC

Winsten

Karoon Energy Says Search for New CFO Well Advanced

25 feb 2026, 22:39 UTC

Winsten

Karoon Energy Says CFO Ray Church to Leave Company

25 feb 2026, 22:39 UTC

Winsten

Karoon Energy Says On-Market Share Buyback Program Ongoing at Moderated Level

25 feb 2026, 22:38 UTC

Winsten

Karoon Energy Says Guidance for 2026 Key Metrics Unchanged

Peer Vergelijking

Prijswijziging

Avita Therapeutics Inc Prognose

Koersdoel

By TipRanks

-16.51% neerwaarts potentieel

12 Maanden Prognose

Gemiddelde 4.5 USD -16.51%

Hoogste 5.5 USD

Laagste 3.5 USD

Gebaseerd op 3 Wall Street-analisten die 12-maands prijsdoelen bieden voor Avita Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

3 ratings

Buy

Hold

Sell

Gebaseerd op 3 analisten die aandelenratings hebben gegeven aan Avita Therapeutics Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

8.83 / 9.77Steun & Weerstand

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Avita Therapeutics Inc

AVITA Medical, Inc., together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions. It develops RECELL GO to control the manual process of disaggregation, filtration, and soak time. The company was formerly known as AVITA Therapeutics, Inc. AVITA Medical, Inc. was incorporated in 2020 and is headquartered in Valencia, California.